Darlifarnib

N/A

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameDarlifarnib
Drug Alias NameKO2806KO-2806
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein farnesyltransferase inhibitors
TargetsProtein farnesyltransferase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKura Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesKura Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A